Abstract Number: 1358 • 2016 ACR/ARHP Annual Meeting
Response of Hidradenitis Suppurativa to Biologic Therapy
Response of Hidradenitis Suppurativa to Biologic Therapy Background/Purpose: Hidradenitis suppurativa (HS) is a chronic, debilitating inflammatory disease of apocrine sweat glands, characterized by recurrent abscessing…Abstract Number: 2001 • 2016 ACR/ARHP Annual Meeting
Perioperative Use of Synthetic Disease-Modifying Anti-Rheumatic Drugs or Tumor Necrosis Factor α Inhibitors Does Not Associate with Increased Rates of Post-Operative Infections
Background/Purpose: The aim of the study is to assess whether the risk of post-operative infectious complications in rheumatoid arthritis (RA) patients undergoing surgical procedures is…Abstract Number: 2628 • 2016 ACR/ARHP Annual Meeting
Retention of Use and Safety of Subcutaneous Abatacept in Rheumatoid Arthritis: A Patient Record Assessment in a Compassionate Use Programme in South Africa, a Tuberculosis Endemic Country
Background/Purpose: South Africa is a tuberculosis (TB) endemic country having one of the highest TB infection rates in the world with close to 1000 cases…Abstract Number: 3066 • 2016 ACR/ARHP Annual Meeting
Risk of Incident Cancer with Biologic and Tofacitinib Therapy in Rheumatoid Arthritis
Background/Purpose: The immune system recognizes, controls, and eliminates tumors through a process of immunosurveillance. In RA, where there is an increased incidence of lymphoma and…Abstract Number: 14 • 2016 ACR/ARHP Annual Meeting
Failure Predictors to Anti-Tumor Necrosis Antagonists in Patients with Chronic Arthritis: Results of a National Registry Biobadasar
Background/Purpose: to analyze failure predictors to anti-tumor necrosis (TNF) therapy in patients who have switched these drugs during chronic arthritis treatment. Methods: BIOBADASAR is a…Abstract Number: 1360 • 2016 ACR/ARHP Annual Meeting
Discontinuation Causes of Biological Therapies: Over a Five-Year Period. Biobadasar
Background/Purpose: To analyze discontinuation causes of biologics therapies (bDMARDs) in patients who are registered in the database BIOBADASAR. Methods: Database included demographics of patients, type…Abstract Number: 2006 • 2016 ACR/ARHP Annual Meeting
Tuberculosis Incidence in Ankylosing Spondylitis, Psoriatic Arthritis, and Other Spondyloarthropathies in Sweden: A Population-Based Cohort Study
Background/Purpose: Patients with rheumatoid arthritis (RA) are at a well-documented increased risk of tuberculosis (TB) compared to the general population, both with and without treatment…Abstract Number: 2629 • 2016 ACR/ARHP Annual Meeting
Serious Adverse Events in Patients with RA Taking Abatacept Compared with Other Dmards. Results from a US-Wide Safety Registry
Background/Purpose: Observational studies are critical in assessing medication safety and effectiveness in the real world. Nonrandom assignment can provide insight to how and when medications…Abstract Number: 3093 • 2016 ACR/ARHP Annual Meeting
Comparison of Changes in Cardiovascular Risk-Associated Biomarkers in RA Patients Treated with Anti-TNF or Other Biological Agents: A Metabolic Study from a Randomized Trial
Background/Purpose: Considering the increased cardiovascular risk in RA patients and the influence of biologics, especially tocilizumab (TCZ) on the lipid profile, we aimed to investigate…Abstract Number: 15 • 2016 ACR/ARHP Annual Meeting
Adverse Events and Persistency of Biologics in Rheumatoid Arthritis Patients with Interstitial Lung Disease
Background/Purpose: RA associated ILD (RA-ILD) is reported as 1-58% depending on the study population and the definition of ILD, and RA-ILD is known to be…Abstract Number: 1501 • 2016 ACR/ARHP Annual Meeting
The Incidence of Interstial Lung Disease and Malignancies in Veterans with Rheumatoid Arthritis
Background/Purpose: Rheumatoid arthritis (RA) is a systemic disease with a known association with lymphoma and interstitial lung disease (ILD). ILD is a frequent extraarticular manifestation…Abstract Number: 2232 • 2016 ACR/ARHP Annual Meeting
Above-Label Dosing with Biologics in Treatment-NaïVe and Treatment-Experienced Patients with Moderate-to-Severe Psoriatic Arthritis
Title: Above-Label Dosing with Biologics in Treatment-Naïve and Treatment-Experienced Patients with Moderate-to-Severe Psoriatic Arthritis Authors: S. Schwartzman*1, Y. Li2, H. Zhou3, V. Herrera2, J. Palmer2…Abstract Number: 2633 • 2016 ACR/ARHP Annual Meeting
Effect of Different Biologic Agents on Lipid Profile in Rheumatoid Arthritis
Background/Purpose: o examine any change between different biologic agents on lipid profile of RA patients. Methods: Patients affected by RA, according to the 2010 EULAR/ACR…Abstract Number: 3094 • 2016 ACR/ARHP Annual Meeting
Factors Associated with Initial or Subsequent Choice of Biologic Disease Modifying Antirheumatic Drugs for the Treatment of Rheumatoid Arthritis
Background/Purpose: Treatment with disease-modifying antirheumatic drugs (DMARDs) is considered the standard of care for rheumatoid arthritis (RA). Over the past two decades, major advances have…Abstract Number: 18 • 2016 ACR/ARHP Annual Meeting
The Impact of Disease-Related and Contextual Factors on Work Outcomes in Chronic Inflammatory Arthritis Patients Treated with Biologics: A Systematic Review
Background/Purpose: Biological therapy has been shown to have a positive effect on work outcomes, such as work participation and/or work disability in patients with chronic…
- « Previous Page
- 1
- …
- 11
- 12
- 13
- 14
- 15
- …
- 26
- Next Page »